Format

Send to

Choose Destination
Am J Surg. 2004 Nov;188(5):532-7.

Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.

Author information

1
Department of Surgery, Box 3118 Medical Center, Duke University Medical Center, Durham, NC 27710, USA.

Abstract

BACKGROUND:

Regional infusion therapy with melphalan (LPAM) is an accepted treatment for advanced extremity melanoma. However, much room exists for improving the therapeutic index of this type of therapy.

METHODS:

Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft. Additional rats were treated systemically with TMZ, or regionally with LPAM or 10% dimethyl sulfoxide (DMSO; control) using ILI.

RESULTS:

Rats that received systemic TMZ showed a poor tumor response and no tumor regression. In contrast, intra-arterial TMZ demonstrated a prolongation of tumor growth delay in a dose-responsive manner. In comparison with LPAM of equitoxic dose, TMZ provided both longer tumor growth delay and a greater number of tumor regressions.

CONCLUSIONS:

These data suggest that ILI with TMZ is an effective treatment for advanced extremity melanoma and may be better than LPAM in this setting.

PMID:
15546565
DOI:
10.1016/j.amjsurg.2004.07.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center